Suscriptores   Asóciese  
Textos Completos Autorizados
PAPEL DE LOS BIFOSFONATOS PARA EL TRATAMIENTO DE LAS METASTASIS OSEAS Y EL MANTENIMIENTO DE LA SALUD OSEA

v-estudie-lo-mejor.gif
Expertos Invitados





PAPEL DE LOS BIFOSFONATOS PARA EL TRATAMIENTO DE LAS METASTASIS OSEAS Y EL MANTENIMIENTO DE LA SALUD OSEA

(especial para SIIC © Derechos reservados)
El ácido zoledrónico es el único bifosfonato que mostró una reducción estadísticamente significativa en la incidencia y en el comienzo de las complicaciones esqueléticas, en comparación con placebo, en pacientes con metástasis óseas por cáncer de próstata, de pulmón y otros tumores sólidos.
lipton9.jpg Autor:
Allan Lipton
Columnista Experto de SIIC

Institución:
Milton S. Hershey Medical Center

Artículos publicados por Allan Lipton
Recepción del artículo
10 de Marzo, 2005 		Primera edición
3 de Octubre, 2005 		Segunda edición, ampliada y corregida
7 de Junio, 2021

PAPEL DE LOS BIFOSFONATOS PARA EL TRATAMIENTO DE LAS METASTASIS OSEAS Y EL MANTENIMIENTO DE LA SALUD OSEA

Resumen
La mayoría de los pacientes con cáncer avanzado presentan metástasis óseas dolorosas y debilitantes que están asociadas con morbilidad esquelética a largo plazo. Las lesiones óseas provocan complicaciones esqueléticas clínicamente significativas como dolor óseo, fracturas patológicas y compresión de la médula espinal. El beneficio clínico con ácido zoledrónico –bifosfonato de tercera generación– para la prevención de complicaciones esqueléticas en pacientes con patología ósea metastásica fue revisado previamente (Lipton A. Cancer Invest. 2002; 20[suppl 2]:45-54). Se vio que el ácido zoledrónico es al menos tan efectivo como el pamidronato para el tratamiento de complicaciones esqueléticas en pacientes con metástasis en los huesos secundarias a cáncer de mama, y es el único bifosfonato que mostró una reducción estadísticamente significativa en la incidencia y en el comienzo de dichas complicaciones, en comparación con placebo, en pacientes con metástasis por cáncer de próstata, de pulmón y de otros tumores sólidos. En este trabajo presentamos una importante puesta al día con respecto a nuestra investigación previamente publicada y que mostró el beneficio de los bifosfonatos para la reducción del dolor óseo en pacientes con enfermedad metastásica, para la prevención de la pérdida ósea inducida por el tratamiento del cáncer y metástasis óseas en pacientes con enfermedad no metastásica.

Palabras clave
Bifosfonatos, metástasis óseas, salud ósea


Artículo completo
(castellano)
Extensión:  +/-10.41 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

ROLE OF BISPHOSPHONATES FOR THE MANAGEMENT OF BONE METASTASES AND THE MAINTENANCE OF BONE HEALTH

Abstract
The majority of patients with advanced cancer develop painful and debilitating bone metastases that are associated with long-term skeletal morbidity. Bone lesions lead to clinically significant skeletal complications including bone pain, pathologic fractures, and spinal cord compression. The clinical benefit of the third-generation bisphosphonate zoledronic acid for the prevention of skeletal complications in patients with metastatic bone disease has been previously reviewed (Lipton A. Cancer Invest. 2002;20[suppl 2]:45-54). Zoledronic acid has been shown to be at least as effective as pamidronate for the treatment of skeletal complications in patients with bone metastases secondary to breast cancer, and is the only bisphosphonate that has demonstrated a statistically significant reduction in the incidence and onset of skeletal complications compared with placebo in patients with bone metastases from prostate cancer, lung cancer, and other solid tumors. Herein, we present important updates to the information reviewed in the previous publication, as well as recent data that have emerged demonstrating the benefit of bisphosphonates for the reduction of bone pain in patients with metastatic disease and for the prevention of cancer treatment-induced bone loss and bone metastases in patients with nonmetastatic disease.

Key words
Bisphosphonates, bone metastases, bone health


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Oncología
Relacionadas: Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 10.41 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
  1. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9(suppl 4):14-27.
  2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-176.
  3. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer [Published erratum in: J Clin Oncol 2004;22:1351]. J Clin Oncol. 2003;21:4042-4057.
  4. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
  5. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882.
  6. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-2621.
  7. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387.
  8. Kohno N, Aogi K, Minami H, Nakamura S, Asaga. T., Iino Y, et al. Zoledronic acid reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer. Poster presented at: 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, Texas. Abstract 3060.
  9. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082-1090.
  10. Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 2004;111:306-312.
  11. Diel IJ, Body J-J, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer. 2004;40:1704-1712.
  12. Saad F, Gleason D, Murray R, Venner P, Goas JA, Chen B-L, et al. Long-term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone [poster]. Poster presented at: American Urological Association Annual Meeting; April 26-May 1, 2003; Chicago, Illinois. Abstract 1473.
  13. Gnant M, Jakesz R, Mlineritsch B, Luschin-Ebengreuth G, Schmid M, Menzel C, et al. Zoledronic acid inhibits cancer treatment-induced bone loss in premenopausal patients with breast cancer who are receiving adjuvant endocrine treatment. Poster presented at: Primary Therapy of Early Breast Cancer 9th International Conference. St. Gallen, Switzerland, January 26-29, 2005. Abstract 103 [abstract].
  14. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948-955.
  15. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008-2012.
  16. Powles T, McCloskey E, Kurkilahti M. Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial [abstract]. Proc Am Soc Clin Oncol. 2004;23:9. Abstract 528.
  17. Jaschke A, Bastert G, Solomayer EF, Costa S, Schuetz F, Diel IJ. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow—a longtime follow-up [abstract]. Proc Am Soc Clin Oncol. 2004;23:9. Abstract 529.
  18. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol. 1998;16:2038-2044.
  19. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Glück S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol. 1999;17:846-854.
  20. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744.
  21. Andersen PK, Gill RD. Cox’s regression model for counting processes: a large sample study. Ann Stat. 1982;10:1100-1120.
  22. Major PP, Cook RJ, Chen B-L, Zheng M. Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: a survival-adjusted cumulative incidence analysis [abstract]. Proc Am Soc Clin Oncol. 2004;23:739. Abstract 8058.
  23. Body JJ, Diel IJ, Lichinitzer MR, Lazarev AF, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90:1133-1137.
  24. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14:1399-1405.
  25. Clézardin P. The antitumor potential of bisphosphonates. Semin Oncol. 2002;29(suppl 21):33-42.
  26. Rack BK, Janni W, Schindlbeck C, Strobl B, Blankenstein T, Rjosk D, et al. Effects of zoledronate on persisting isolated tumor cells (ITC) in the bone marrow (BM) of patients without recurrence of early breast cancer [abstract]. Proc Am Soc Clin Oncol. 2004;23:834. Abstract 9515.
  27. Diel IJ, Solomayer E-F, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339:357-363.
  28. Coleman R, Gralow J, Bell R, Lipton A, on behalf of the AZURE and SWOG (0307)/Intergroup investigators. Zoledronic acid is being investigated for the prevention of bone metastases in patients with early stage breast cancer [poster]. Presented at: What is New in Bisphosphonates Seventh Workshop on Bisphosphonates—From the Laboratory to the Patient; March 24-26, 2004; Davos, Switzerland. Poster 66.
  29. Carroll PR, Altwein J, Brawley O, et al. Management of disseminated prostate cancer. In: Denis L, Bartsch G, Khoury S, Murai M, Partin A, Eds. Prostate Cancer: 3rd International Consultation on Prostate Cancer—Paris. Paris, France: Health Publications; 2003:251-284.
  30. Piga A, Bracci R, Ferretti B, Sandri P, Nortilli R, Acito L, et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res. 1998;17:213-217.
  31. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98:962-969.
  32. Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer. 2003;97(suppl):789-795.
  33. Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology. 2002;60(suppl 1):79-85.
  34. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997;15:955-962.
  35. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997;15:1341-1347.
  36. Smith MR, Lee WC, Krupsi T, Brandman J, Wang Q, Botteman M, et al. Association between androgen deprivation therapy and fracture risk: a population-based cohort study in men with non-metastatic prostate cancer [abstract]. Proc Am Soc Clin Oncol. 2004;23:382. Abstract 4507.
  37. Smith MR, Fallon MA, Goode MJ. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology. 2003;61:127-131.
Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
 Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517